natgillin/translations-raw huggingface dataset:
In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p < 0.001).
V študiji revmatoidnega artritisa IV je bil odziv 20 po ACR pri bolnikih, zdravljenih z zdravilom Humira in standardno oskrbo, statistično značilno boljši kot pri bolnikih, zdravljenih s placebom in standardno oskrbo (p < 0,001).
In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table 3).
V študiji revmatoidnega artritisa V pri bolnikih z zgodnjim revmatoidnim artritisom, ki še niso dobivali metotreksata, je kombinirana terapija z zdravilom Humira in metotreksatom po 52 tednih prinesla hitrejše in značilno večje odzive ACR kakor monoterapija z metotreksatom ali monoterapija z zdravilom Humira, odzivi pa so se ohranili do 104. tedna (glejte preglednico 3).
In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table 5).
V študiji revmatoidnega artritisa V pri bolnikih z zgodnim revmatoidnim artritisom, ki še niso dobivali metotreksata, je kombinirana terapija z zdravilom Humira in metotreksatom po 52 tednih prinesla hitrejše in značilno večje odzive ACR kakor monoterapija z metotreksatom ali monoterapija z zdravilom Humira, odzivi pa so se ohranili do 104. tedna (glejte preglednico 5).
In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table 5).
V študiji revmatoidnega artritisa V pri bolnikih z zgodnjim revmatoidnim artritisom, ki še niso dobivali metotreksata, je kombinirana terapija z zdravilom Humira in metotreksatom po 52 tednih prinesla hitrejše in značilno večje odzive ACR kakor monoterapija z metotreksatom ali monoterapija z zdravilom Humira, odzivi pa so se ohranili do 104. tedna (glejte preglednico 5).
In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table 7).
V študiji revmatoidnega artritisa V pri bolnikih z zgodnjim revmatoidnim artritisom, ki še niso dobivali metotreksata, je kombinirana terapija z zdravilom Humira in metotreksatom po 52 tednih prinesla hitrejše in značilno večje odzive ACR kakor monoterapija z metotreksatom ali monoterapija z zdravilom Humira, odzivi pa so se ohranili do 104. tedna (glejte preglednico 7).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 5).
V študiji revmatoidnega artritisa V so strukturno okvaro sklepov ocenili rentgenografsko in jo izrazili kot razliko v modificirani celotni Sharpovi oceni (glejte preglednico 5).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 5).
V študiji revmatoidnega artritisa V so strukturno okvaro sklepov ocenili rentgenografsko in jo izrazili kot razliko v modificirani celotni Sharpovi oceni (glejte preglrdnico 5).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 7).
V študiji revmatoidnega artritisa V so strukturno okvaro sklepov ocenili rentgenografsko in jo izrazili kot razliko v modificirani celotni Sharpovi oceni (glejte preglednico 7).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 7).
V študiji revmatoidnega artritisa V so strukturno okvaro sklepov ocenili rentgenografsko in jo izrazili kot razliko v modificirani celotni Sharpovi oceni (glejte preglrdnico 7).
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 9).
V študiji revmatoidnega artritisa V so strukturno okvaro sklepov ocenili rentgenografsko in jo izrazili kot razliko v modificirani celotni Sharpovi oceni (glejte preglednico 9).
In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 showed greater improvement (p < 0.001) for Humira/methotrexate combination therapy versus methotrexate monotherapy and Humira monotherapy at week 52, which was maintained through Week 104.
V študiji revmatoidnega artritisa V sta se indeks invalidnosti HAQ in telesna komponenta SF 36 ob kombinirani terapiji z zdravilom Humira in metotreksatom po 52 tednih izboljšala bolj (p < 0,001) kot ob monoterapiji z metotreksatom ali ob monoterapiji z zdravilom Humira ; to se je ohranilo do 104. tedna.
In RA-I and RA-II, Cimzia-treated patients reported significant improvements in physical function as assessed by the Health Assessment Questionnaire – Disability Index (HAQ-DI) and in tiredness (fatigue) as reported by the Fatigue Assessment Scale (FAS) from Week 1 through to the end of the studies compared to placebo.
V študijah RA-I in RA-II je bilo v primerjavi s placebom od 1. tedna do konca študij opaziti pomembno izboljšanje fizične funkcije, ki so jo pri bolnikih, ki so dobivali zdravila Cimzia, ovrednotili z indeksom nezmožnosti na osnovi vprašalnika za oceno zdravstvenega stanja (Health Assessment Questionnaire – Disability Index (HAQ-DI)), ter utrujenosti po lestvici FAS.
In rabbit studies with bazedoxifene, abortion and an increased incidence of heart (ventricular septal defect) and skeletal system (ossification delays, misshapen or misaligned bones, primarily of the spine and skull) anomalies in the fetuses were present at maternally toxic dosages of  0.5 mg/kg/day (1.5 times the human exposure).
V študijah bazedoksifena na kuncih so se pri odmerkih  0,5 mg/kg/dan (izpostavljenost, 1,5-krat večja od tiste pri človeku), ki so bili toksični za mater, pri plodovih pojavljali splav in zvečana incidenca anomalij srca (defekt prekatnega pretina) in skeleta (zapoznelo zakostenevanje skeleta, deformirane ali napačno razvrščene kosti, predvsem hrbtenice in lobanje).
In rabbits abortion occurred in conjunction with maternal toxicity at exposures below the human therapeutic range.
Pri zajcih je prišlo do splava v povezavi s toksičnostjo za samico pri izpostavljenosti pod terapevtskim območjem pri ljudeh.
In rabbits, abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
Pri kuncih je po odmerkih, ki so pri samici povzročili pomembno toksičnost, prišlo do abortusa ali zgodnje absorpcije, vključno s smrtjo.
In rabbits, cladribine is teratogenic at doses of 3.0 mg/kg/day (given on gestation days 7-19).
Pri kuncih je kladribin teratogen v odmerkih 3,0 mg/kg/dan (danih na dneve gestacije 7–19).
In rabbits, coadministration was poorly tolerated in many mothers, resulting in death, moribundity or abortion.
Pri kuncih so številne samice-matere sočasno uporabo slabo prenašale in je povzročila smrt, moribundnost ali splav.
In rabbits, Econor was investigated in a field study involving 1,152 weaned rabbits.
Pri kuncih so zdravilo Econor proučevali v terenski študiji, v katero je bilo vključenih 1 152 odstavljenih kuncev.
In rabbits, IVEMEND caused initial transient local acute inflammation following paravenous, subcutaneous and intramuscular administration.
Pri kuncih je zdravilo IVEMEND po paravenski, subkutani in intramuskularni aplikaciji povzročilo začetno prehodno lokalno akutno vnetje.
In rabbits, lapatinib was associated with maternal toxicity at 60 and 120 mg/kg/day (8% and 23% of the expected human clinical exposure, respectively) and abortions at 120 mg/kg/day.
Pri kuncih je bil lapatinib pri odmerkih 60 in 120 mg/kg/dan (8–odstotna oziroma 23-odstotna izpostavljenost človeka pri klinični uporabi) povezan s toksičnimi učinki za mater in abortusi pri odmerku 120 mg/kg/dan.
In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000 mg/kg (0.40 times the 50 mg twice daily human clinical exposure based on AUC).
Pri kuncih so toksične učinke pri samicah materah (zmanjšano uživanje hrane, nezadostno izločanje/brez izločanja blata/urina, zavrto pridobivanje telesne mase) opažali pri 1000 mg/kg (0,40-kratnik klinične izpostavljenosti pri človeku med uporabo 50 mg dvakrat na dan na podlagi AUC).
In rabbits, oral, maternally toxic, doses of brinzolamide of up to 6 mg/kg/day (261 times the recommended daily clinical dose of 23 µg/kg/day) revealed no effect on foetal development.
Pri kuncih peroralni in za samice toksični odmerki brinzolamida do 6 mg/kg/dan (261-kratnik priporočenega kliničnega dnevnega odmerka 23 µg/kg/dan) niso pokazali nobenih učinkov na razvoj ploda.
In rabbits, reductions in gravid uterine weights and number of live foetuses were due to increases in the number of resorptions, increases in post-implantation loss and complete litter loss in 4 of 6 pregnant females at plasma exposure levels 3 times the systemic exposure in humans.
Pri kuncih sta bila zmanjšanje gravidne uterine mase in števila živih plodov posledica večjega števila resorpcij, večje poimplantacijske izgube in popolne izgube legla pri 4 od 6 brejih samic, in sicer pri plazemski izpostavljenosti, ki je bila 3-krat večja od sistemske izpostavljenosti pri ljudeh.
In rabbits, systemic exposure at the high dose level was only 0.3 times human exposure at the maximum clinical dose and thus the development toxicity of fosamprenavir has not been fully determined.
Sistemska izpostavljenost kuncev po največjem odmerku je bila enaka le 0,3-kratni izpostavljenosti pri človeku po največjem kliničnem odmerku in tako škodljiv vpliv fosamprenavirja na razvoj ni bil podrobno preučen.
In radioligand binding assays using a broad panel of animal and human receptors, ion channels and transporters no significant binding was found.
Pri študijah vezave radioligandov ob uporabi širokega spektra animalnih in humanih receptorjev, ionskih kanalčkov ter transporterjev niso ugotovili nobene značilne vezave.
In randomised clinical studies, a subcutaneous dose of 23 MU/m2/day (230 micrograms/m2/day) or rather 4-8.4 micrograms/kg/day was used.
V randomiziranih kliničnih preskušanjih so uporabljali subkutani odmerek 23 M e./m2/dan (230 mikrogramov/m2/dan) oziroma 4-8,4 mikrogramov/kg/dan.
In randomised clinical studies, a subcutaneous dose of 230 micrograms/m2/day (4.0 to 8.4 micrograms/kg/day) was used.
V randomiziranih kliničnih preskušanjih so uporabljali subkutani odmerek 230 mikrogramov/m2/dan (4,0 do 8,4 mikrogramov/kg/dan).
In randomised clinical trials, a subcutaneous dose of 230 micrograms/m2/day (4.0 to 8.4 micrograms/kg/day) was used.
V randomiziranih kliničnih študijah so uporabili subkutani odmerek 230 mikrogramov/m2/dan (4,0 do 8,4 mikrogramov/kg/dan).
In randomised study CC-4047-MM-003, 302 patients with relapsed and refractory multiple myeloma were exposed to 4 mg pomalidomide administered once daily for 21 days of each 28 day cycle in combination with a weekly low dose of dexamethasone.
V randomizirani študiji (CC-4047-MM-003) sta bila 302 bolnika s ponovljenim in na zdravljenje odpornim diseminiranim plazmocitomom izpostavljena 4 mg pomalidomida, danim enkrat na dan za 21 dni vsakega 28-dnevnega cikla v kombinaciji z nizkim tedenskim odmerkom deksametazona.
In randomised, controlled, double-blind clinical trials (including developmental and postmarketing experience), over 17,000 patients with type 2 diabetes have been treated with Onglyza .
V randomiziranih, kontroliranih, dvojno slepih kliničnih preskušanjih (vključno z izkušnjami med obdobjem razvoja in po začetku trženja zdravila) je zdravilo Onglyza prejemalo več kot 17.000 bolnikov s sladkorno boleznijo tipa 2.
In randomised, controlled, double-blind clinical trials (including developmental and postmarketing experience), over 17,000 patients with type 2 diabetes have been treated with saxagliptin.
V randomiziranih, kontroliranih, dvojno slepih kliničnih preskušanjih (vključno z izkušnjami med obdobjem razvoja in po začetku trženja zdravila) je saksagliptin prejemalo več kot 17.000 bolnikov s sladkorno boleznijo tipa 2.
In randomised, placebo-controlled clinical trials, filgrastim did not increase the incidence of undesirable effects associated with cytotoxic chemotherapy.
V randomiziranih, s placebom nadzorovanih kliničnih preskušanjih filgrastim ni povečal incidence neželenih učinkov, povezanih s citotoksično kemoterapijo.
In randomised, placebo-controlled clinical trials, filgrastim did not increase the incidence of undesirable effects associated with cytotoxic chemotherapy.
V randomiziranih, s placebom nadzorovanih kliničnih preskušanjih filgrastim ni povzročil povečanja števila neželenih učinkov, povezanih s citotoksično kemoterapijo.
In rare and isolated cases, the following side effects have been reported with immunoglobulin preparations: severe hypersensitivity reactions such as a sudden fall in blood pressure or anaphylactic shock (e.g. you may feel light-headed, dizzy, faint on standing, cold in the hands and feet, sense an abnormal heart beat or chest pain, or have blurred vision) even when you have shown no hypersensitivity on previous infusions,
V redkih in posameznih primerih so pri pripravkih imunoglobulina poročali o naslednjih neželenih učinkih: hudih preobčutljivostnih reakcijah, kot je nenadno znižanje krvnega tlaka ali anafilaktični šok (npr. občutek prazne glave, omotičnosti, omedlevice v stoječem položaju, občutek mraza v rokah in nogah, občutek nenavadnega srčnega utripa ali bolečine v prsih ali zamegljen vid), celo kadar preobčutljivosti ni bilo pri predhodnih infundiranjih;
In rare and more severe cases, this may – as a consequence – lead to the occurrence of dehydration, hypokalaemia, blood bicarbonate decrease, dizziness, and orthostatic hypotension.
V redkih in hudih primerih lahko to povzroči dehidracijo, hipokaliemijo, znižane ravni hidrogenkarbonata v krvi, omotico in ortostatsko hipotenzijo.
In rare cases , neurological signs (e.g. incoordination, tremor, ataxia, convulsions, mydriasis and impaired vision) have been observed.
V redkih primerih so opazili nevrološke znake (npr. nekoordinacijo, tremor, ataksijo, konvulzije, midriazo in okvarjen vid).
In rare cases , slight apathy or reduction in appetite may be observed, which should resolve spontaneously.
V redkih primerih opazimo apatijo in slabši apetit, ki spontano preidejo.
In rare cases , slight apathy or reduction in appetite may be observed, which should resolve spontaneously.
V redkih primerih opazimo apatijo in slabši apetit, ki spontano preideta.
In rare cases allergic reactions may be severe. new or unusual pain in your hip, groin or thigh (this may be an early indication of a possible fracture of the thigh bone).
V redkih primerih so alergijske reakcije lahko hude. nova ali neobičajna bolečina v kolku, dimljah ali stegnenici (to je lahko zgoden znak možnega zloma stegnenice).
In rare cases development of alopecia has also been observed.
Zasledili so še redke primere alopecije.
In rare cases digestive signs (e.g. diarrhoea, ruminant stomach disorder) have been observed.
V redkih primerih so opazili prebavne znake (npr. drisko, motnje v vampu).
In rare cases gastrointestinal signs such as diarrhoea and vomiting or anorexia and decreased activity are possible.
V redkih primerih so možni tudi gastrointestinalni znaki, kot so driska, bruhanje ali neješčnost, in zmanjšana aktivnost.
In rare cases in cats and in very rare cases in dogs, application site reactions such as transitory scratching, erythema, alopecia or dermatitis at the application site may occur.
V redkih primerih se pri mačkah in v zelo redkih primerih pri psih na mestu nanosa zdravila lahko pojavi prehodno praskanje, pordelost kože, izpadanje dlake ali dermatitis.
In rare cases in cats, neurological signs (e.g. incoordination, tremor, ataxia, convulsions, mydriasis and impaired vision) have been observed.
V redkih primerih so pri mačkah opazili nevrološke znake (npr. nekoordinacijo, tremor, ataksijo, konvulzije, midriazo in okvarjen vid).
In rare cases liver failure was observed (rare: may affect up to 1 in 1,000 people).
Redko so poročali o jetrni odpovedi (redko: pojavi se lahko pri največ 1 od 1000 bolnikov).
In rare cases severe hypersensitivity reactions following administration of Zenapax have been reported (see section 4.4).
V redkih primerih so se po dajanju Zenapaxa pojavile resne preobčutljivostne reakcije (glejte poglavje 4.4).
In rare cases severe liver impairment has been described, including cholestasis, icterus, hepatic necrosis and hepatic failure with fatal outcome (see sections 4.8 and 4.5).
V redkih primerih so opisali hudo okvaro jeter, vključno s holestazo, zlatenico, nekrozo jeter in odpovedjo jeter s smrtnim izidom (glejte poglavji 4.8 in 4.5).
In rare cases the MAH will not be able to produce a MACI implant from the available cells.
V redkih primerih imetnik dovoljenja za promet z zdravilom ne uspe izdelati vsadka zdravila MACI iz razpoložljivih celic.
In rare cases this can also happen independently of OHSS (see also in section 2. under “Blood clotting problems).
V redkih primerih lahko pride do tega neodvisno od OHSS (glejte tudi poglavje 2 pod „Težave s strjevanjem krvi“).
In rare cases transient diarrhoea, anorexia or lethargy may be observed.
V redkih primerih so opazili prehodno drisko, anoreksijo ali letargijo.
In rare cases, application site reactions such as transitory scratching, erythema, alopecia or dermatitis at the application site may occur.
V redkih primerih se lahko pojavijo reakcije na mestu nanosa, kot na primer prehodno praskanje, pordelost kože, izpadanje dlake ali dermatitis.
In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders).
V redkih primerih, ko se imunski sistem okrepi, lahko napade tudi zdrava telesna tkiva (avtoimune bolezni).
In rare cases, behavioural disorder signs such as hyperactivity, vocalisation or anxiety, systemic signs such as lethargy or anorexia, and neurological signs such as muscle tremor have been reported.
Redko so opažene vedenjske spremembe kot so hiperaktivnost, vokalizacija ali tesnobnost, sistemski znaki kot so letargija ali anoreksija in nevrološki znaki kot je mišični tremor.
In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs.
V redkih primerih so pri uporabnicah COC poročali o nastanku benignih jetrnih tumorjev, še redkeje pa o malignih jetrnih tumorjih.
In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs.
V redkih primerih so pri uporabnicah KPK poročali o nastanku benignih jetrnih tumorjev, še redkeje pa o malignih jetrnih tumorjih.
In rare cases, haemorrhagic or necrotising pancreatitis occurs.
Redko nastane hemoragični ali nekrozantni pankreatitis.
In rare cases, inappetence, fever, shivering and diffuse oedematous swellings (e.g. facial oedema, swollen muzzle/upper lip) may be observed.
Redko lahko opazimo anoreksijo, vročino , tresenje in difuzne edematozme otekline (npr. facialni edem, otečen gobec/ gornja ustnica).
In rare cases, liver tumours which are not cancer have been found in women taking combined hormonal contraceptives.
Pri ženskah, ki uporabljajo kombinirane hormonske kontraceptive poročajo o redkih primerih nerakavih tumorjev na jetrih in še redkejših rakavih tumorjih na jetrih.
In rare cases, pain at palpation, sneezing or conjunctivitis (eye inflammation) may be noted, that resolves without any treatment.
V redkih primerih se lahko pojavijo na otip bolečine, kihanje ali konjunktivitis(vnetje oči), ki preidejo brez zdravljenja.
In rare cases, pain at palpation, sneezing or conjunctivitis (eye inflammation) may be noted, that resolves without any treatment.
V redkih primerih se lahko pojavijo na otip bolečine, kihanje ali konjunktivitis, ki preidejo brez zdravljenja.
In rare cases, pain at palpation, sneezing or conjunctivitis may be noted, that resolves without any treatment.
V redkih primerih se lahko pojavijo na otip bolečine, kihanje ali konjunktivitis, ki preidejo brez zdravljenja.
In rare cases, slight scaling, transient erythema and alopecia can be observed, which usually disappear spontaneously without treatment.
V redkih primerih lahko opazimo rahlo luščenje, prehodno rdečino in alopecija, ki običajno izginejo spontano brez zdravljenja.
In rare cases, slight scaling, transient erythema and alopecia can be observed, which usually disappear spontaneously without treatment.
V redkih primerih lahko opazimo rahlo luščenje, prehodno rdečino in alopecijo, ki običajno izginejo spontano brez zdravljenja.
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 4.8).
V redkih primerih je zaradi obstoja takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper- ali hipoglikemiji (glejte poglavje 4.8).
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).
V redkih primerih je zaradi obstoja takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper- ali hipoglikemiji (glejte poglavje 5.1).
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.
V redkih primerih je zaradi prisotnosti insulinskih protiteles treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper- ali hipoglikemiji.
In rare cases, the reactions after the second dose of vaccine may remain for 14 days.
Redko lahko reakcija po drugem odmerku cepiva traja 14 dni.
In rare cases, there may be pain on being touched, sneezing or conjunctivitis (eye inflammation).
V redkih primerih se lahko pojavijo bolečine na otip, kihanje ali konjunktivitis (vnetje oči).
In rare instances, blood clots (thromboses) that formed inside a blood vessel, broke off, and traveled inside the bloodstream to block another blood vessel (thromboembolism) have been associated with Elonva therapy as with other gonadotropins.
V redkih primerih so bili z zdravilom Elonva, tako kot z ostalimi gonadotropini, povezani krvni strdki (trombi), ki nastanejo znotraj krvne žile, se odtrgajo in potujejo po krvnem obtoku in zamašijo drugo krvno žilo (tromboembolizem).
In rare instances, very serious rash has been reported which can be potentially life-threatening.
V redkih primerih so poročali o zelo nevarnem izpuščaju, ki je lahko življenjsko nevaren.
In rare occasions swelling can reach a diameter up to 15–20 cm, with duration up to 2–3 weeks, that may require symptomatic treatment.
V redkih primerih se lahko pojavi oteklina s premerom do 15-20 cm, ki traja do 2-3 tedne in lahko zahteva simptomatsko zdravljenje.
In rare occasions, swelling can reach a diameter up to 15–20 cm, with duration up to 2–3 weeks, that may require symptomatic treatment.
V redkih primerih se lahko pojavi oteklina s premerom do 15 – 20 cm, ki traja od 2 – 3 tedne in lahko zahteva simptomatsko zdravljenje.
In rare occasions, swelling can reach a diameter up to 15–20 cm, with duration up to 2–3 weeks, that may require symptomatic treatment.
V redkih primerih se lahko pojavi oteklina s premerom do 15-20 cm, ki traja do 2-3 tedne in lahko zahteva simptomatsko zdravljenje.